What kind of next-generation sequencer is MiniSeq?

親子鑑定 NIPPT DNA鑑定 ヒロクリニック  検査

Summary of this article

MiniSeq is a type of Next Generation Sequencer (NGS), a compact and user-friendly sequencer from Illumina, Inc. MiniSeq is an instrument that enables rapid analysis of DNA and RNA in the laboratory. It is mainly used for small-scale genome analysis, targeted sequencing, and gene expression analysis.

Main features of MiniSeq

Compact design:

  • MiniSeq is much smaller than Illumina’s other sequencers and is designed to be easily installed in limited space in the laboratory. This provides an environment where next-generation sequencing technology can be easily used.

Easy operation:

  • MiniSeq is designed to be easy to handle for the NGS novice with intuitive software and automated protocols. The integrated workflow from sample preparation to data analysis makes it simple and fast to obtain results.

Ideal for targeted sequencing:

  • MiniSeq is ideal for targeted region sequencing (sequencing to analyze a specific gene or genomic region). It is widely used in studies such as analysis of cancer-related genes, genetic testing for hereditary diseases, and identification of microorganisms.

Cost-effective sequence:

  • Optimized for small-scale projects, it can be used in laboratories with limited budgets because of its lower initial investment and running costs compared to large-scale next-generation sequencers.

Rapid data acquisition:

  • The MiniSeq provides rapid sequencing for small samples. In a typical experiment, samples are often analyzed in less than a day, making it ideal for studies that require rapid results.

MiniSeq Technology

MiniSeq uses a reversible terminator-based sequencing technology (SBS: Sequencing by Synthesis) developed by Illumina. This technology has the following features

Sequencing Bisynthesis (SBS) technology:

  • SBS is a method of reading nucleotide sequences one base at a time using a synthetic reaction of DNA. As fluorescently labeled nucleotides are incorporated according to the DNA template, each base is detected sequentially and the DNA sequence is determined.

Read length and data throughput:

  • The MiniSeq can adjust the length of sequencing reads (length of sequence to be read) from 100 base pairs (bp) to as low as 150 bp. In addition, data throughput is designed for small projects and can generate data volumes up to 7.5 Gb.
親子鑑定 NIPPT DNA鑑定 唾液

MiniSeq Applications

The MiniSeq is used in a variety of research fields. The main applications are as follows

Target sequencing:

  • It is used for sequencing of specific genes or genomic regions. It is used to test for cancer-related genes, genetic diseases, and to identify microorganisms.

Gene expression analysis:

  • MiniSeq also supports RNA sequencing, which is used to measure gene expression levels. This allows analysis of gene expression patterns under specific conditions to investigate disease and therapeutic response.

Microbial genome analysis:

  • It is used for genome analysis of microorganisms and identification of pathogens, and has been applied to research on infectious diseases and antibiotic resistance.

Cancer Research:

  • MiniSeq is used to analyze genetic mutations and tumor-related biomarkers in cancer. Targeted sequencing allows rapid identification of specific genetic mutations in cancer cells.

summary:

MiniSeq is a compact, easy-to-use next-generation sequencer from Illumina designed primarily for small-scale projects such as targeted sequencing and gene expression analysis. It offers rapid data acquisition and cost-effective operation, and is suitable for a wide range of laboratory applications.

医師監修 監修日:2024年10月19日

岡 博史 (おか ひろし)

医師・医学博士 ヒロクリニック統括院長

YouTubeチャンネルなどを通じて、遺伝子やNIPT(新型出生前診断)についてわかりやすく発信しています。

略歴

  • 1996年 慶應義塾大学医学部 卒業
  • 2004年 慶應義塾大学 医学博士号 取得
  • 2005年 慶應義塾大学 皮膚科学教室 助手
  • 2008年 ヒロ皮フ形成クリニック 開業
  • 2009年 医療法人社団福美会 理事長
  • 2015年 医療法人社団福美会 理事

資格・所属

  • CAPラボディレクター
  • 日本皮膚科学会 皮膚科専門医
  • 日本医師会 産業医
  • 東京衛生検査所 指導監督医

この記事は、 ヒロクリニックNIPPTの編集・監修体制 にもとづき、資格を持つ医師が内容を確認しています。

医師監修 監修日:2024年10月19日

堤 修一 (つつみ しゅういち)

医師・医学博士 ヒロクリニック博多駅前院 院長

略歴

  • 1993年 東京大学医学部医学科 卒業
  • 2016〜2019年 東京大学先端科学技術研究センター 准教授

発信・関連リンク

この記事は、 ヒロクリニックNIPPTの編集・監修体制 にもとづき、資格を持つ医師が内容を確認しています。

参考文献

  1. Ravi RK, Walton K, Khosroheidari M. Next-Generation Sequencing. Methods Mol Biol. 2018;1706:1-21.
  2. Goodwin S, McPherson JD, McCombie WR. Coming of age: ten years of next-generation sequencing technologies. Nat Rev Genet. 2016;17(6):333-351.

Supervisor of the article


Dr. Hiroshi Oka

Director of CAP Laboratory

Graduated from Keio University, Faculty of Medicine

Doctor of Medicine

Medical Doctor